# **I FTTFRS**

# Black intraocular lenses: near infra-red light transmission may risk treatment failure

Intractable diplopia occurs in approximately 0.8% of patients following strabismus surgery, with considerable detriment to visual quality of life. Long-term therapeutic occlusion is required to permit functional vision.

Black intraocular lens (IOL) implantation is an effective therapeutic option associated with high rates of postoperative


satisfaction. Black IOL implantation entails a cost to the public sector or patient but this may be offset by long-term clinical and social benefits and fewer hospital visits.

A distinction has emerged between black IOLs that transmit near-infrared (NIR) light and those producing total occlusion of all wavelengths of light (figure 1).<sup>2</sup> Morcher black IOLs transmit NIR light exponentially from 720 nm, with 100% transmission over 820 nm, permitting posterior segment imaging with scanning laser ophthalmoscopy (SLO) and optical coherence tomography (OCT).<sup>2</sup> This property offers a distinct clinical advantage; SLO/OCT may detect life-threatening retinal and optic nerve diseases, such as choroidal melanoma.<sup>2</sup>

The intended benefit of black IOL implantation is occlusion of light. Enigmatic perception of light across NIR-transmitting black IOLs has been reported widely without any consensus on the mechanism of light perception. <sup>1</sup> <sup>3–5</sup> Four hypotheses have been suggested: (1) Perception of light by long-wavelength, L-cone photoreceptors due to NIR light transmission across Morcher black IOLs<sup>2</sup> <sup>5</sup> (2) Para-optical light leakage in patients with large scotopic pupil diameters, <sup>4</sup> (3) Light transmission across the intact sclerochoroidal tunic, <sup>4</sup> (4) Non-organic light perception.

Retrospective examination of all black IOL case series reported in the literature (table 1) strongly supports the hypothesis

# **NIR-transmitting Black IOLs**








Morcher 6S Black PMMA IOL




Morcher 80D Black Lotus IOL (foldable)

# Non NIR-transmitting Black IOLs



Artisan Blackiris-claw 201 IOL



DrSchmidt's Black PMMA 612 IOL

Figure 1 Black IOLs in clinical use. Near-infrared (NIR)-transmitting black IOLs: (A) 85F PMMA IOL (6 mm optic, 12 mm overall), (B) 6S PMMA IOL (10 mm optic, 12 mm overall), (C) 80D PMMA IOL (6 mm optic, 13.5 mm overall). All NIR-transmitting Black Lotus 80D PMMA IOL are manufactured by Morcher GmbH, Stuttgart, Germany. Non NIR-transmitting black IOLs: (D) Artisan Black iris-claw IOL (201, polycarbonate, 5.4 mm optic 8.5 mm overall, manufactured by Ophtec BV, Groningen, Netherlands), (E) Black PMMA IOL (612, 6 mm optic, 12 mm overall, manufactured by Dr Schmidt Intraocularlinsen, Sankt Augustin, Germany).

Table 1 Evidence for light perception through NIR-transmitting black IOLs

		Number of patients with visual acuity of light perception or better in the occluded eye		Number of patients experiencing	NIR-transmitting black IOL
Case series	Cases reported	Preoperative	Postoperative	light perception despite black IOL	and model number
Wong <i>et al</i> <sup>3</sup>	6	2	2	2 (100%)	Morcher (81D, 85F)
Lee <i>et al</i> <sup>4</sup>	3	3	1	1* (33%)	Morcher (80D, 80D/6S, 81D)
Hadid, Wride <i>et al</i> 1	12	12	12	12 (100%)	Morcher (81D)
Yusuf <i>et al</i> <sup>5</sup> and Yusuf <i>et al</i> , 2013 (unpublished)	2	2	2	2 (100%)	Morcher (85F)
Total	23	19	17	17 (89%)	

Summary of all published cases documenting the preoperative and postoperative visual acuities of patients undergoing near-infrared transmitting black IOL implantation.

\*Both patients who experienced no perception of light in the occluded eye postoperatively in this series had optic neuropathies—post-traumatic and demyelinating, respectively.

of NIR light perception across NIR-transmitting black IOLs as the primary mechanism underlying treatment failure—defined as troublesome persistence of light perception or diplopia despite black IOL implantation.

Twenty-three patients have been reported across four case series, which document preoperative and postoperative visual acuities of patients implanted with NIR-transmitting black IOLs<sup>1 3–5</sup> (table 1). Twenty-one patients (91%) recorded light perception vision through the black IOL postoperatively.

Two patients experienced complete occlusion of light after NIR-transmitting black IOL implantation<sup>4</sup>; both patients had optic neuropathies documented preoperatively (compressive and demyelinating, respectively). Optic neuropathies are associated with loss of red–green chromatic discrimination due to effects on parvocellular pathways representing long-wavelength cone photoreceptors<sup>6</sup>; such patients are unlikely to perceive long-wavelength NIR light.

Clinical observations further discount the alternative hypotheses of light perception following black IOL implantation. Light perception has been reported in a patient with formal scotopic pupillometry (6.5 mm pupil) despite implantation of a NIR-transmitting black IOL with a 10 mm occlusive optic (figure 1B). This observation makes paraoptical light transmission highly unlikely.

We have experience of a patient with chronic, debilitating light perception despite implantation of an NIR-transmitting black IOL, who underwent secondary implantation of a NIR-blocking Artisan iris-claw IOL (figure 1D) fixed over the pupillary margin with enclavation. This patient recorded no light perception postoperatively, discounting the hypothesis of light penetrating the intact sclerochoroidal tunic (Yusuf *et al*, unpublished). There is no evidence for a non-organic aetiology as a basis for light perception in these case series.

The recent discovery of NIR-transmission across some black IOLs in clinical use<sup>2</sup> may clarify the unusual observations in clinical reports that preceded it. Establishing the mechanism of light perception in such cases is critical to preventing and managing treatment failure. The mechanism of light perception in patients with NIR-transmitting black IOLs is stimulation of L-cone photoreceptors in NIR-rich light environments such as incandescent and solar light, provided the stimulus is sufficiently bright. An 850 nm light-emitting diode (LED) (Osram GmbH, Munich, Germany) used in our previous studies is visible to the unaided eye, yet falls outside the visible range (380–740 nm).<sup>2</sup>

This insight may inform the design of an optimal black IOL occlusive to all light wavelengths below 820 nm—minimising light perception—but permitting SLO/OCT imaging of the posterior pole (SLO/OCT superluminescent diodes operate at 820–870 nm).

Patients undergoing NIR-transmitting black IOL implantation must be counselled that perception of light is to be expected postoperatively during informed consent. The presented evidence suggests that light perception following NIR-transmitting black IOL implantation is the rule, not the exception.

# Imran H Yusuf, 1,2 Stuart N Peirson, 1 C K Patel2

<sup>1</sup>Nuffield Laboratory of Ophthalmology, Oxford University, John Radcliffe Hospital, Oxford, Oxfordshire,

<sup>2</sup>The Oxford Eye Hospital, John Radcliffe Hospital, Oxford, Oxfordshire, UK

Correspondence to Dr C K Patel, The Oxford Eye Hospital, John Radcliffe Hospital, Oxford OX3 9DU, UK; ckpatel@btinternet.com

**Acknowledgements** Stuart N. Peirson's research is funded in part by the Wellcome Trust.

**Contributors** IHY, SNP and CKP wrote the manuscript.

**Competing interests** Stuart N. Peirson's research is funded in part by the Wellcome Trust. None of the authors have any financial interest in any product, method or material or lack thereof mentioned in this article.

**Provenance and peer review** Not commissioned; externally peer reviewed.





**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**To cite** Yusuf IH, Peirson SN, Patel CK. *Br J Ophthalmol* 2013;**97**:1353–1354.

Received 28 March 2013 Revised 12 June 2013 Accepted 16 June 2013 Published Online First 31 July 2013

Br J Ophthalmol 2013;**97**:1353–1354. doi:10.1136/bjophthalmol-2013-303474

### **REFERENCES**

- Hadid OH, Wride NK, Griffiths PG, et al. Opaque intraocular lens for intractable diplopia: experience and patients' expectations and satisfaction. Br J Ophthalmol 2008;92:912–5.
- Yusuf IH, Peirson SN, Patel CK. Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use. J Cataract Refract Surg 2012;38: 513–18.
- 3 Wong SC, Islam N, Ficker L. Black occlusive IOLs. *Ophthalmology* 2007;114:2365.
- 4 Lee RM, Dubois VD, Mavrikakis I, et al. Opaque intraocular lens implantation: a case series and lessons learnt. Clin Ophthalmol 2012;6: 545–9.
- 5 Patel CK, Yusuf IH, Menezo V. Imaging the macula through a black occlusive intraocular lens. Arch Ophthalmol 2010:128:1374–6.
- 6 Flanagan P, Zele AJ. Chromatic and luminance losses with multiple sclerosis and optic neuritis measured using dynamic random luminance contrast noise. Ophthalmic Physiol Opt 2004;24:225–33.